Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Edralbrutinib + Ublituximab + Umbralisib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Edralbrutinib||TG-1701|TG 1701|TG1701|EBI-1459|EBI1459|EBI 1459|SHR 1459|SHR1459||BTK inhibitor 29||Edralbrutinib (TG-1701) is a second-generation irreversible BTK inhibitor, which may result in decreased downstream signaling and reduced tumor growth (PMID: 34551904).|
|Ublituximab||LFB-R603|TG-1101|TG-20|TGTX-1101||CD20 Antibody 14||Ublituximab (TG-1101) is a monoclonal antibody that targets CD20 that may induce complement-dependent and antibody-dependent cell-mediated cytotoxicity against B-cells expressing CD20, potentially resulting in increased B-cell death (PMID: 23611989, PMID: 32351164).|
|Umbralisib||Ukoniq||RP5264|TGR-1202||PIK3CD inhibitor 26||Ukoniq (umbralisib) is a selective inhibitor of PIK3CD, which prevents Akt phosphorylation and induces cytotoxicity (J Clin Oncol 32:5s, 2014 (suppl; abstr 2513), PMID: 30709431). Ukoniq (umbralisib) is FDA approved for use in adult patients with relapsed or refractory marginal zone lymphoma with one or more prior anti-CD20-based therapy, and in adult patients with relapsed or refractory follicular lymphoma who have three or more prior lines of therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03671590||Phase I||Edralbrutinib Edralbrutinib + Ublituximab + Umbralisib||Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies||Recruiting||2|